GENET archive

[Index][Thread]

5-Animals: Milk expression vector kit for transgenic protein production



mailinglist genet-news
-------------------------
-----------------------------------------------------------------

TITLE:  Genzyme Transgenics' Invitrogen Announce Launch of Milk
        Expression Vector Kit For Transgenic Protein Production
SOURCE: Genzyme, webmaster@genzyme.com
DATE:   April 15, 1999

-----------------------------------------------------------------

Genzyme Transgenics' Invitrogen Announce Launch of Milk Expression Vector Kit For Transgenic Protein Production

Genzyme Transgenics Corporation and Invitrogen Corp. today announced market launch of the pBC1 Milk Expression Vector Kit, providing researchers with proprietary technology for the production of recombinant proteins in the milk of transgenic mice. For the first time, researchers in the United States and Europe can apply specialized tools to perform quick, cost-effective feasibility studies of therapeutic proteins utilizing transgenic production.

The pBC1 Milk Expression Vector Kit contains Genzyme Transgenics’ beta casein expression promoter and other proprietary DNA sequences, enabling researchers to insert a gene of interest into the DNA of a fertilized mouse ovum, to produce selected proteins in the milk of a transgenic mouse. The kit allows expression of proteins in transgenic mice at levels significantly higher than those obtained from mammalian cell culture or prokaryotes. Use of the pBC1 kit is limited to the generation of transgenic animals for early-stage feasibility studies only. However, protein production levels obtained in mouse systems are generally predictive of larger animal systems. If initial feasibility studies are favorable, then researchers would be required to contract with Genzyme Transgenics for commercial use.

"Putting our enabling technology in the hands of many researchers may lead to more biopharmaceuticals being developed transgenically, providing potential new commercial opportunities for the company," said Michael Young, vice president, commercial development for Genzyme Transgenics Corporation. "The pBC1 kit offers our customers an extremely efficient and powerful tool for the expression of recombinant proteins, and enhances our commitment to provide leading-edge expression systems," said Dr. Patrick Dillon, chief technical officer for Invitrogen.

Invitrogen will manufacture, market, and distribute the kits to customers in the United States and Europe. Genzyme Transgenics provided the proprietary gene promoter, expression technology, and technical expertise necessary for initial production and will receive royalties based on net product sales.

For more information about the pBC1 Milk Expression Vector Kit, contact Invitrogen at (800)-955-6288, extension 2.

Genzyme Transgenics Corporation applies transgenic technology to enable the development and production of recombinant proteins and monoclonal antibodies for medical uses. Primedica Corporation provides preclinical development and testing services to pharmaceutical, biotechnology, medical device and other companies. Genzyme Transgenics Corporation is also developing idiotypic vaccines in collaboration with the National Cancer Institute.

Invitrogen is a global leader in technologies for gene cloning and expression. The company develops, manufactures, and markets research tools in kit form and provides research services to corporate, academic, and government entities. These research kits simplify and improve gene cloning, gene expression, and gene analysis techniques, as well as other molecular biology activities. Invitrogen also provides gene cloning and expression services on a contract basis using its "high-throughput" gene cloning and expression technology. Founded in 1987, the company is headquartered in San Diego, California and operates a European center with manufacturing, sales and distribution in Groningen, Netherlands.

This news release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Potential risks and uncertainties include, but are not limited to, the ability of researchers to generate transgenic mice successfully, the predictability of expression levels in larger animals, Invitrogen's ability to market Genzyme Transgenics’ expressions system successfully, market acceptance of the research kit, and Genzyme Transgenics’ ability to generate scale-up and commercialization agreements stemming from this distribution agreement.

Editor's Note:
Genzyme Transgenics Corporation's releases are available on the World Wide Web at
http://www.genzyme.com/transgenics.



-----------------------------------------------------------------


===================================================
-| Hartmut Meyer
-| Co-ordinator
-| GENET
-| The European NGO Network on Genetic Engineering
-|
-| Reinhaeuser Landstr. 51
-| D - 37083 Goettingen
-| Germany
-| 
-| phone: #49-551-7700027
-| fax  : #49-551-7701672
-| email: genet@agoranet.be
===================================================

Genet News
---------